Breast Cancer
From the Journals
ICYMI: Hereditary cancer screening feasible in community gynecologic practices
Conference Coverage
HDAC/aromatase inhibitor combo shows promise for HR+/HER2- advanced breast cancer
MUNICH – Chidamide + exemestane combination therapy increased PFS by about 4 months, compared with exemestane...
Conference Coverage
PALOMA-3: Overall survival better for endocrine-sensitive patients only
MUNICH –
Conference Coverage
Finally, immunotherapy shows benefit in TNBC
MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...
News
Talazoparib approved for HER2-negative advanced breast cancer
The
Expert Commentary
New and promising GSM treatments, more clinical takeaways from NAMS 2018
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
Feature
Tech-based cancer company raises access concerns
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...
Conference Coverage
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
Article
Agrees that OC use clearly reduces mortality
Conference Coverage
Breast cancer patients getting unnecessary scans against recommendations
PHOENIX – Despite ASCO recommendations, many patients with early-stage breast cancers at low metastasis risk have undergone imaging tests for...
Latest News
Top cancer researcher fails to disclose corporate financial ties in major research journals
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in...